首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   285877篇
  免费   20275篇
  国内免费   1231篇
耳鼻咽喉   3213篇
儿科学   8595篇
妇产科学   5274篇
基础医学   37356篇
口腔科学   5354篇
临床医学   27704篇
内科学   60456篇
皮肤病学   4214篇
神经病学   26079篇
特种医学   9163篇
外国民族医学   11篇
外科学   43232篇
综合类   4771篇
一般理论   331篇
预防医学   23419篇
眼科学   8029篇
药学   20386篇
  6篇
中国医学   634篇
肿瘤学   19156篇
  2023年   1406篇
  2022年   2924篇
  2021年   6549篇
  2020年   3871篇
  2019年   6106篇
  2018年   6957篇
  2017年   5162篇
  2016年   5887篇
  2015年   6783篇
  2014年   9897篇
  2013年   13470篇
  2012年   20321篇
  2011年   21232篇
  2010年   11907篇
  2009年   10615篇
  2008年   18289篇
  2007年   19108篇
  2006年   18986篇
  2005年   18591篇
  2004年   17512篇
  2003年   16170篇
  2002年   15018篇
  2001年   2920篇
  2000年   2461篇
  1999年   3043篇
  1998年   3367篇
  1997年   2769篇
  1996年   2403篇
  1995年   2303篇
  1994年   1917篇
  1993年   1720篇
  1992年   1754篇
  1991年   1553篇
  1990年   1428篇
  1989年   1367篇
  1988年   1323篇
  1987年   1301篇
  1986年   1297篇
  1985年   1282篇
  1984年   1474篇
  1983年   1342篇
  1982年   1501篇
  1981年   1409篇
  1980年   1253篇
  1979年   933篇
  1978年   895篇
  1977年   815篇
  1976年   723篇
  1975年   640篇
  1974年   654篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
6.
Gestational trophoblastic neoplasia (GTN) patients are treated according to the eight-variable International Federation of Gynaecology and Obstetrics (FIGO) scoring system, that aims to predict first-line single-agent chemotherapy resistance. FIGO is imperfect with one-third of low-risk patients developing disease resistance to first-line single-agent chemotherapy. We aimed to generate simplified models that improve upon FIGO. Logistic regression (LR) and multilayer perceptron (MLP) modelling (n = 4191) generated six models (M1-6). M1, all eight FIGO variables (scored data); M2, all eight FIGO variables (scored and raw data); M3, nonimaging variables (scored data); M4, nonimaging variables (scored and raw data); M5, imaging variables (scored data); and M6, pretreatment hCG (raw data) + imaging variables (scored data). Performance was compared to FIGO using true and false positive rates, positive and negative predictive values, diagnostic odds ratio, receiver operating characteristic (ROC) curves, Bland-Altman calibration plots, decision curve analysis and contingency tables. M1-6 were calibrated and outperformed FIGO on true positive rate and positive predictive value. Using LR and MLP, M1, M2 and M4 generated small improvements to the ROC curve and decision curve analysis. M3, M5 and M6 matched FIGO or performed less well. Compared to FIGO, most (excluding LR M4 and MLP M5) had significant discordance in patient classification (McNemar's test P < .05); 55-112 undertreated, 46-206 overtreated. Statistical modelling yielded only small gains over FIGO performance, arising through recategorisation of treatment-resistant patients, with a significant proportion of under/overtreatment as the available data have been used a priori to allocate primary chemotherapy. Streamlining FIGO should now be the focus.  相似文献   
7.
8.
Colorectal cancer (CRC) is the third most diagnosed cancer and the second leading cause of cancer-related mortality in the United States. Across the globe, people in the age group older than 50 are at a higher risk of CRC. Genetic and environmental risk factors play a significant role in the development of CRC. If detected early, CRC is preventable and treatable. Currently, available screening methods and therapies for CRC treatment reduce the incidence rate among the population, but the micrometastasis of cancer may lead to recurrence. Therefore, the challenge is to develop an alternative therapy to overcome this complication. Nanotechnology plays a vital role in cancer treatment and offers targeted chemotherapies directly and selectively to cancer cells, with enhanced therapeutic efficacy. Additionally, nanotechnology elevates the chances of patient survival in comparison to traditional chemotherapies. The potential of nanoparticles includes that they may be used simultaneously for diagnosis and treatment. These exciting properties of nanoparticles have enticed researchers worldwide to unveil their use in early CRC detection and as effective treatment. This review discusses contemporary methods of CRC screening and therapies for CRC treatment, while the primary focus is on the theranostic approach of nanotechnology in CRC treatment and its prospects. In addition, this review aims to provide knowledge on the advancement of nanotechnology in CRC and as a starting point for researchers to think about new therapeutic approaches using nanotechnology.  相似文献   
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号